Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial

[1]  P. K. Sharma.  Atherosclerosis. , 2020, The Journal of the Association of Physicians of India.

[2]  F. Rosendaal,et al.  Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk , 2019, Clinical epidemiology.

[3]  S. Cannegieter,et al.  Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review , 2019, Seminars in Thrombosis and Hemostasis.

[4]  F. Tabet,et al.  Biology, pathophysiology and current therapies that affect lipoprotein (a) levels. , 2019, Journal of molecular and cellular cardiology.

[5]  A. Van der Laarse,et al.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia , 2019, Annals of clinical biochemistry.

[6]  F. Rosendaal,et al.  Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial , 2019, Journal of thrombosis and haemostasis : JTH.

[7]  D. Girelli,et al.  Apolipoprotein C-III Strongly Correlates with Activated Factor VII–Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation , 2019, Thrombosis and Haemostasis.

[8]  F. Rosendaal,et al.  Rosuvastatin use improves measures of coagulation in patients with venous thrombosis , 2018, European heart journal.

[9]  A. Sahebkar,et al.  Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. , 2018, Journal of clinical lipidology.

[10]  A. Van der Laarse,et al.  Robust and Accurate 2-Year Performance of a Quantitative Mass Spectrometry-Based Apolipoprotein Test in a Clinical Chemistry Laboratory. , 2018, Clinical chemistry.

[11]  F. Rosendaal,et al.  Lipid levels and risk of venous thrombosis: results from the MEGA-study , 2017, European Journal of Epidemiology.

[12]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[13]  S. Tsimikas.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[14]  D. Strickland,et al.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) , 2016, The Journal of Biological Chemistry.

[15]  A. Zito,et al.  Rosuvastatin: Beyond the cholesterol-lowering effect. , 2016, Pharmacological research.

[16]  A. Sahebkar,et al.  The impact of statin therapy on plasma levels of von Willebrand factor antigen , 2015, Thrombosis and Haemostasis.

[17]  A. Van der Laarse,et al.  Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. , 2016, Clinical chemistry.

[18]  J. Moake,et al.  Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings , 2015, PloS one.

[19]  J. Braspenning,et al.  Measurement of Blood Coagulation Factor Synthesis in Cultures of Human Hepatocytes. , 2015, Methods in molecular biology.

[20]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[21]  P. Reitsma,et al.  Modulation of Mouse Coagulation Gene Transcription following Acute In Vivo Delivery of Synthetic Small Interfering RNAs Targeting HNF4α and C/EBPα , 2012, PloS one.

[22]  J. Sundquist,et al.  Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: a nationwide epidemiological study. , 2012, Thrombosis research.

[23]  T. Okano,et al.  Hepatocyte Is a Sole Cell Type Responsible for the Production of Coagulation Factor IX In Vivo. , 2012, Cell medicine.

[24]  M. Prins,et al.  Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory , 2008, Thrombosis and Haemostasis.

[25]  R. Blaheta,et al.  Long‐term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[26]  H. Milionis,et al.  A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. , 2007, Clinical therapeutics.

[27]  C. Mannhalter,et al.  Low‐density lipoprotein receptor‐related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism , 2007, Journal of thrombosis and haemostasis : JTH.

[28]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[29]  A. Zwinderman,et al.  LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study , 2005, Current medical research and opinion.

[30]  L. Havekes,et al.  LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. , 2005, Blood.

[31]  K. Mann,et al.  Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[32]  M. Vázquez-Carrera,et al.  Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4. , 2005, British journal of pharmacology.

[33]  J. Gamble,et al.  High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity , 2004, Circulation.

[34]  G. Walldius,et al.  Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy , 2004, Journal of internal medicine.

[35]  D. Rader,et al.  Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. , 2003, The American journal of cardiology.

[36]  A. Federici.  The factor VIII/von Willebrand factor complex: basic and clinical issues. , 2003, Haematologica.

[37]  J. Mckenney,et al.  Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. , 2002, American heart journal.

[38]  T. Lüscher,et al.  Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.

[39]  E. Tremoli,et al.  Cholesterol-induced Thrombogenicity of the Vessel Wall: Inhibitory Effect of Fluvastatin , 2002, Thrombosis and Haemostasis.

[40]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[41]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[42]  F. Rosendaal,et al.  The role of dyslipidemia and statins in venous thromboembolism , 2001, Current controlled trials in cardiovascular medicine.

[43]  José A Fernández,et al.  Plasma Lipoproteins, Hemostasis and Thrombosis , 2001, Thrombosis and Haemostasis.

[44]  P. Libby,et al.  An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.

[45]  W L Haskell,et al.  Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. , 1998, The New England journal of medicine.

[46]  K. Mann,et al.  Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[47]  C. Byrne,et al.  Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. , 1998, Blood.

[48]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[49]  W. Harris,et al.  The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. , 1993, The New England journal of medicine.

[50]  W. Kannel,et al.  Risk factors for pulmonary embolism: The Framingham study , 1983 .